Quantcast
Last updated on April 16, 2014 at 16:54 EDT

Latest Chronic obstructive pulmonary disease Stories

Almost Half Of COPD Diagnoses Are Wrong
2013-05-22 12:56:06

Peter Suciu for redOrbit.com — Your Universe Online A new study has found that chronic obstructive pulmonary disease (COPD) is over-diagnosed among uninsured patients. Researchers found that over 40 percent of patients being treated for COPD at federally funded clinics did not actually have the disease. COPD is a progressive lung disease that leads to the loss of lung function and is primarily caused by smoking. The disease causes coughing, wheezing, shortness of breath, chest...

2013-05-22 04:21:01

OXFORD, England, May 22, 2013 /PRNewswire/ -- First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung...

2013-05-21 08:29:37

Boehringer Ingelheim also presents new data from a Phase 2 study demonstrating increased bronchodilation with 5 mcg tiotropium as an add-on therapy in symptomatic patients with moderate persistent asthma at the American Thoracic Society International Conference (ATS 2013) RIDGEFIELD, Conn., May 21, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of...

2013-05-20 08:27:34

--Demonstration of ASM-024 adjunctive benefit with current treatments in pre-clinical asthma models-- QUEBEC CITY, May 20, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of four studies of ASM-024, Asmacure's lead compound in development for asthma and chronic obstructive pulmonary disease...

2013-05-20 08:25:53

MADISON, Wis., May 20, 2013 /PRNewswire/ -- Asthmapolis (az-MAP-o-lis), the FDA-cleared mobile health solution for asthma and COPD, today announced CEO David Van Sickle will give an invited presentation during Respiratory Drug Delivery (RDD(®)) Europe 2013 in Berlin, Germany. On Friday, May 24 at 8:30 a.m., Van Sickle will present "Monitoring and Improving Compliance and Asthma Control: Mapping Inhaler Use for Feedback to Patients, Physicians and Payers" as part of the session track,...

2013-05-17 08:23:49

Data on investigational compounds and an approved product will be presented RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler®...

2013-05-17 08:23:25

Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray will become the only available short-acting bronchodilator offering two different medicines in a single inhaler RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and patients that the transition...

2013-05-16 08:28:33

QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound, currently in...

2013-05-13 16:27:17

Portable device enhances patient mobility; now available in U.S. market AUSTIN, Texas, May 13, 2013 /PRNewswire/ -- A new High Frequency Chest Wall Oscillation (HFCWO) vest that gives respiratory patients the freedom to move around during treatments is now available in the United States, International Biophysics Corporation (IBC) announced today. The AffloVest - already widely prescribed in Europe - represents a major advancement in the treatment of respiratory diseases such as...

2013-05-10 16:24:28

LONDON and SOUTH SAN FRANCISCO, Calif., May 10, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients...